• Explore /
  • Poster
  • / Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).

Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).

Abstract Poster

Authors

null

Arkadiusz Z. Dudek

HealthPartners, St. Paul, MN

Arkadiusz Z. Dudek , Xiaofei F. Wang , Lin Gu , Tom Stinchcombe , Robert Arthur Kratzke , Everett E. Vokes , Hedy L. Kindler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Mesothelioma

Clinical Trial Registration Number

NCT01085630

Citation

J Clin Oncol 37, 2019 (suppl; abstr 8517)

DOI

10.1200/JCO.2019.37.15_suppl.8517

Abstract #

8517

Poster Bd #

273

Abstract Disclosures

Similar Posters

First Author: Rina Hui

First Author: Peter Wojciech Szlosarek

First Author: Helena Alexandra Yu

First Author: Inkeun Park